Enhanced Permeability of Rasagiline Mesylate through Nasal In-situ Gel: A Central Composite Design Study

DOI

10.2991/978-94-6463-813-4_7How to use a DOI?

Keywords

Rasagiline mesylate (RM); MAO-B inhibitor; Parkinson's disease; Nasal in-situ gel; Drug availability; Poloxamer 407; N-dodecyl-β-D-maltoside (DDM); Central Composite Design (CCD); Mucoadhesive strength; Permeability coefficient

Abstract

Transmucosal nasal drug delivery has become a major player in the field of drug delivery technology during the past few decades as a non-invasive method. “Rasagiline mesylate (RM) is a MAO-B inhibitor used in the treatment of idiopathic Parkinson's disease”, currently available in oral solid dose formulations with an absolute oral bioavailability of 36%. This study focuses on formulating a RM “nasal in-situ gel to enhance” drug availability at the site of action. Poloxamer 407 and N-dodecyl-β-D-maltoside (DDM) were selected as independent variables in the formulation process. A two-level, “two-factor Central Composite Design (CCD) was employed to investigate the impact of polymer concentrations on the dependent variables”. HPMC was used as a viscosity modifier. Statistical analysis identified the most effective formulation within the design space. The optimized formulation was evaluated using ATR and DSC studies, and for pH, viscosity, gelation, drug content, and spreadability. The results indicated that increasing “the concentration of Poloxamer 407 increased gelation time” and mucoadhesive strength without significantly affecting drug permeability. Conversely, variations in DDM concentration did not notably impact gelation time and mucoadhesive strength but had a direct effect on the permeability coefficient. This study underscores the crucial roles of Poloxamer 407 and DDM in optimizing RM nasal in-situ gel formulations for improved permeation of RM drug delivery to the site of action.

Copyright

© 2025 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

TY  - CONF
AU  - Dumpa Rushi Kumar Reddy
AU  - Suryaprakash Reddy
PY  - 2025
DA  - 2025/08/13
TI  - Enhanced Permeability of Rasagiline Mesylate through Nasal In-situ Gel: A Central Composite Design Study
BT  - Proceedings of the International symposium on Sustainable Drug Design and Nanoparticle development: Quantum and Computational Perspectives (SDDNDQCP 2025)
PB  - Atlantis Press
SP  - 75
EP  - 91
SN  - 2468-5739
UR  - https://doi.org/10.2991/978-94-6463-813-4_7
DO  - 10.2991/978-94-6463-813-4_7
ID  - Reddy2025
ER  -